|Articles|January 23, 2023
At-line Spent Media Analysis using the REBEL to Optimize a CHO mAb Fed-Batch Process
Author(s)908 Devices
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How New ADC Modalities Backed by Samsung Could Shape Solid Tumor Treatment
2
Industry Experts Probe CNPV Impacts: Part II
3
What a $2 Billion Maryland Expansion Means for the Future of Biologics Production
4
BioPharm Weekly News Roundup—Week of Nov. 17, 2025
5
